Compare YMM & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YMM | CYTK |
|---|---|---|
| Founded | 2011 | 1997 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1B | 10.7B |
| IPO Year | 2021 | 2004 |
| Metric | YMM | CYTK |
|---|---|---|
| Price | $8.76 | $72.39 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 19 |
| Target Price | $12.00 | ★ $89.26 |
| AVG Volume (30 Days) | ★ 7.0M | 1.8M |
| Earning Date | 05-21-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.04% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,368,000.00 |
| Revenue This Year | N/A | $7.37 |
| Revenue Next Year | $13.05 | $310.19 |
| P/E Ratio | $18.30 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.46 | $44.93 |
| 52 Week High | $14.07 | $88.31 |
| Indicator | YMM | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 45.95 | 40.68 |
| Support Level | $8.27 | $73.34 |
| Resistance Level | $9.52 | $79.66 |
| Average True Range (ATR) | 0.25 | 2.14 |
| MACD | -0.05 | 0.07 |
| Stochastic Oscillator | 43.23 | 27.81 |
Full Truck Alliance Co Ltd, through its subsidiaries, provides comprehensive services for shippers and truckers through its mobile and website platforms. Its principal operations are in the People's Republic of China. The group derives its revenues principally from shippers and trucker's use of its platforms in connection with freight matching services and value-added services.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.